Breaking News

Aeterna Zentaris Changes Name to COSCIENS Biopharma

One of COSCIENS’ lead products is macimorelin, (Macrilen; Ghryvelin) an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., a specialty biopharmaceutical company developing and commercializing a portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, has changes its name effective August 6, 2024.   The shareholders of the company approved a special resolution authorizing the board of directors of the company to effect the name change. There is no change in the capitalization of the Company in connect...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters